Biopsy

Rates of erectile dysfunction and urinary incontinence at 1, 2, and 3 years after radical surgery are not higher among men who have multiple prostate biopsies while on active surveillance for prostate cancer.

Analysis of proteins identified in urine has led to the discovery of proteomic signatures for prostate cancer that have the potential to serve as highly accurate noninvasive biomarkers that can identify aggressive disease before surgery.

Prostate-specific molecular imaging at initial biopsy and preoperative planning can accurately determine and delineate the extent of prostate cancer. The imaging technique was a type of PET/CT called 68Ga-PSMA PET/CT.

RNA test of blood platelets can detect, classify, and pinpoint the location of cancer by analyzing a sample equivalent to 1 drop of blood. Using this new method, researchers were able to identify cancer with 96% accuracy.

Study data suggests that magnetic resonance imaging (MRI) could one day make biopsies more effective, or even replace them altogether, via noninvasive detection of telltale sugar molecules shed by the outer membranes of cancerous cells.